FDA Accepts Precision BioSciences Inc (DTIL) PBCAR19B for treatment of NHL Disease
Precision BioSciences Inc (DTIL), a clinical biotech firm, recently announced that FDA has accepted its application for PBCAR19B as an Investigation New Drug (IND). PBCAR19B is tailored to be the next generation drug having stealth cell and CD19 capabilities and will target patients suffering from Non-Hodgkin Lymphoma(NHL). The company was very pleased to receive the […]
